Bulletin
Investor Alert

London Markets Open in:

Topics

Centers for Disease Control and Prevention

Video

As Kids' Covid-19 Vaccine Nears, Doctors Work to Ease Parent Concerns

  • As Kids' Covid-19 Vaccine Nears, Doctors Work to Ease Parent Concerns As Kids' Covid-19 Vaccine Nears, Doctors Work to Ease Parent Concerns 5:53
    First U.S. Covid-19 Vaccines Roll Out First U.S. Covid-19 Vaccines Roll Out 4:33
3:29 a.m. Nov. 19, 2021 - By Tomi Kilgore
Moderna COVID-19 vaccine booster gets FDA OK for all adultsShare of Moderna Inc. shot up 6.0% in premarket trading Friday, after the biotechnology company said the U.S. Food and Drug Administration has extended the emergency use authorization (EUA) of a booster dose of its COVID-19 vaccine to all adults, aged 18 and older. The booster dose is for those who have completed COVID-19 vaccinations, with any authorized or approved vaccine, at least six months ago. "This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country," said Moderna Chief Executive Stéphane Bancel. Next, an advisory committee of the U.S. Centers for Disease Control and Prevention (CDC) will meet to discuss a potential recommendation for rolling out COVID-19 boosters. Moderna's stock has tumbled 33.1% over the past three months through Thursday but has soared 140.7% year to date, while the S&P 500 has gained 25.3% this year.
11:24 a.m. Nov. 3, 2021 - By Robert Schroeder
'Get your children vaccinated,' Biden urges after shots for kids 5-11 approved President Joe Biden on Wednesday urged parents of young children to get them vaccinated, a day after the Centers for Disease Control and Prevention to the COVID-19 vaccine developed by Pfizer and BioNTech . The decision marked the first opportunity for U.S. children under 12 to get the protection of any COVID-19 vaccine. Speaking at the White House, Biden said vaccines would be available at 20,000 locations across the country, including schools and community health centers. "You can now protect them from this horrible virus," Biden said of young children. The president also addressed a stunning loss by the Democratic candidate in Virginia's gubernatorial election and said voters want the party to "get things done."
8:33 a.m. Sept. 29, 2021 - By Jaimy Lee
CDC urges individuals who are pregnant or trying to get pregnant to get a COVID-19 shotThe Centers for Disease Control and Prevention on Thursday issued a urging those who are pregnant, lactating, and trying to get pregnant to get a COVID-19 vaccine. The public-health agency said 31% of people who are pregnant have been vaccinated, a figure that is much lower than the 65% of people in the U.S. who are eligible for a shot and are fully vaccinated. There have been at least 125,000 pregnant individuals with confirmed cases of COVID-19; 22,000 have been hospitalized and 161 people died. Pregnancy can put people at higher risk of severe illness, hospitalization, and death if they contract the virus. They also have a higher risk of preterm birth, according to the CDC.
8:16 a.m. Sept. 24, 2021 - By Jaimy Lee
CDC: We are not changing the definition of 'fully vaccinated' now that COVID-19 boosters are available The Centers for Disease Control and Prevention does not plan to change the definition of what it means to be "fully vaccinated" right now that BioNTech SE and Pfizer Inc.'s COVID-19 booster shots are available for a large group of the U.S. population. During a White House briefing on Friday, CDC director Rochelle Walensky said "we need to have more experience with our third shot and have more people eligible or recommended to receive it, before we change that definition." The Food and Drug Administration on Wednesday authorized a third booster dose of Pfizer's two-dose vaccine, making it the first vaccine to receive regulatory authorization for a booster. Moderna Inc.'s application for a booster shot for its two-dose vaccine is currently under review at the FDA.
2:34 a.m. Sept. 22, 2021 - By Jaimy Lee
CDC committee to meet today and Thursday to again discuss BioNTech and Pfizer's COVID-19 boosterA Centers for Disease Control and Prevention committee is Wednesday and Thursday to again discuss the science and possible administration plan for BioNTech SE and Pfizer Inc.'s COVID-19 booster shot. The CDC's Advisory Committee on Immunization Practices sets out the guidelines for how vaccines should be used in the U.S. The Food and Drug Administration has not approved or authorized an extra dose of the BioNTech and Pfizer vaccine except in people who are immuno-compromised, and an influential FDA committee last week recommended that boosters to older people and those who are at higher risk of severe disease. Some experts have suggested that the FDA decision is coming this week.
4:29 a.m. Sept. 15, 2021 - By Jaimy Lee
Pfizer cites 'totality' of clinical data in bid for COVID-19 booster approvalShares of Pfizer Inc. gained 0.1% in premarket trading on Wednesday after the drug maker said the "totality" of clinical data indicates that people who are at least 16 years old and were vaccinated with the COVID-19 shot that it developed with BioNTech SE should get a booster after six months. In a published Wednesday morning by the Food and Drug Administration in advance of an advisory committee meeting set for Friday, Pfizer said its Phase 3 substudy examined 306 people between the ages of 18 and 55 years old who got a third dose. It found that an extra dose is considered safe and increased neutralizing antibody titers against the original strain of the virus as well as the beta and delta variants to a higher rate than what was reported after two doses in the clinical trials last year. Younger participants were more likely to report systemic events after the second and third doses than the first dose; fever was more common after the third dose. No adverse events were reported in the first month after the third dose. Pfizer also cited research conducted by Israel, the Centers for Disease Control and Prevention, and the hospital system Kaiser Permanente in the document, saying that data from Israel "suggest reduced effectiveness against severe disease could eventually follow observed reductions in effectiveness against SARS-CoV-2 infections." Pfizer's stock is up 21.4% this year, while the S&P 500 has gained 18.9%.
10:46 a.m. Sept. 2, 2021 - By Jaimy Lee
FDA committee to discuss COVID-19 booster shotsAn influential Food and Drug Administration advisory committee plans to meet Sept. 17 to discuss extra doses of the COVID-19 vaccines, including the application filed by BioNTech SE and Pfizer Inc. for a third dose of their COVID-19 shot. Moderna Inc. on Wednesday also submitted its application for a booster dose of its COVID-19 vaccine. The FDA's Vaccines and Related Biological Products Advisory Committee traditionally recommends whether the FDA should authorize or approve a vaccine or drug. The regulator is not required to follow the advice of the committee but it often does. The Biden administration previously said that COVID-19 booster shots will be available to adults starting Sept. 20, though from the FDA and the Centers for Disease Control and Prevention. "The FDA will review the supplemental application as expeditiously as possible, while still doing so in a thorough and science-based manner," Dr. Peter Marks, the director of the FDA's Center for Biologics Research and Evaluation, said in a on Wednesday.
9:37 a.m. Aug. 26, 2021 - By Jaimy Lee
CDC: Overdoses of ivermectin are risingThere has been a "rapid increase" in prescriptions of ivermectin among people looking to treat or prevent COVID-19 cases, according to a issued Thursday by the Centers for Disease Control and Prevention. Ivermectin is an approved treatment for parasitic worms in animals and some rare conditions in humans, but not COVID-19 infections. "Adverse effects associated with ivermectin misuse and overdose are increasing, as shown by a rise in calls to poison control centers reporting overdoses and more people experiencing adverse effects," the CDC said Thursday. The Food and Drug Administration earlier this week , which is not proven to treat COVID-19. "You are not a horse," the regulator said in a tweet that has since gone viral. The drug is one of several therapies that are but have become a worrisome issue for public-health experts as people seek alternative ways to address COVID-19 infections.
2:14 a.m. Aug. 25, 2021 - By Tomi Kilgore
Coronavirus tally: Daily average of COVID-19 cases rises to 7-month high, as J&J data supports booster shotsThe global tally for the coronavirus-borne illness climbed to 213.30 million as of early Wednesday, while the death toll rose to 4,454,812, according to . The U.S. led the world with a total of 38.08 million cases and 630,838 deaths. The daily average of new cases over the past seven days rose to 151,441 as of Tuesday, up 28% from two weeks ago, and the highest count since Jan. 29, according to . The daily average for deaths increased to 1,116, up 84% in two weeks and the most since March 19. The daily average for hospitalizations of rose to 94,082, up 35% from two weeks ago and the most since Feb. 6. The number of people that have been fully vaccinated grew to 171.4 million, or 51.6% of the total U.S. population, according to , while the number of people who have received at least one dose of a vaccine edged up to 202.04 million, or 60.9% of the total population. Johnson & Johnson announced Wednesday data that supported the use of a COVID-19 vaccine booster shot, eight months after people previously received J&J's single-shot vaccine.
1:22 a.m. Aug. 24, 2021 - By Tomi Kilgore
Coronavirus tally: Daily average for new cases, deaths and hospitalizations keep climbing to multi-month highsThe global tally for the coronavirus-borne illness climbed to above 212.61 million as of early Tuesday, while death toll rose to 4,442,545, according to . The U.S. led the world with a total of 37.94 million cases and 629,411 deaths. The daily average of new cases over the past seven days rose to 150,625 as of Monday, up 29% from two weeks ago, and the highest count since Jan. 30, according to . The daily average for deaths increased to 1,057, up 91 in two weeks and the most since March 24. The daily average for hospitalizations of 93,318 was up 39% from two weeks ago and the most since Feb. 6. The number of people that have been fully vaccinated rose to 171.1 million, or 51.5% of the total U.S. population, according to , while the number of people who have received at least one dose of a vaccine edged up to 201.7 million, or 60.8% of the total population. Hopes that vaccination rates would increase were boosted by the Food and Drug Administration's developed by Pfizer Inc. and BioNTech SE on Monday for people at least 16 years old.
1:51 a.m. Aug. 23, 2021 - By Tomi Kilgore
Coronavirus tally: Average daily U.S. death toll tops 1,000 for first time in 5 months, FDA set to approve Pfizer vaccineThe global tally for the coronavirus-borne illness climbed to 211.9 million as of early Monday, while death toll rose to 4,432,694, according to . The U.S. led the world with a total of 37.71 million cases and 628,503 deaths. The daily average of new cases over the past seven days rose to 149,675 as of Sunday, up 36% from two weeks ago, but down from 150,138 on Saturday, according to . The daily average for deaths increased to 1,008, topping the 1,000 mark for a second-straight day, and up 95% in two weeks, and the most since March 25. Hospitalizations of 92,482 was up 43% from two weeks ago and the most since Feb. 6. The number of people that have been fully vaccinated rose to 170.82 million, or 51.5% of the total U.S. population, according to . The Food and Drug Administration is Pfizer Inc.'s and partner BioNTech SE's COVID-19 vaccine as early as Monday.
1:45 a.m. Aug. 20, 2021 - By Tomi Kilgore
Coronavirus tally: U.S. daily average of COVID-19 cases, deaths and hospitalization rise to multi-month highsThe global tally for the coronavirus-borne illness climbed above 210 million as of early Friday, while death toll rose to 4,404,511, according to . The U.S. led the world with a total of 37.29 million cases and 625,166 deaths. The daily average of new cases over the past seven days rose to 143,827 as of Thursday, up 44% from two weeks ago and the most since Feb. 1, according to . The daily average for deaths increased to 911, up 108% in two weeks, and the most since March 31, while hospitalizations of 86,877 was up 53% from two weeks ago and the most since Feb. 9. The number of people that have been fully vaccinated rose to 169.59 million, or 51.1% of the total U.S. population, according to . AstraZeneca PLC said Friday that in a late stage trial. "There were no cases of severe Covid-19 or Covid-19-related deaths in those treated with AZD7442," the company said.
1:36 a.m. Aug. 19, 2021 - By Tomi Kilgore
Coronavirus tally: Global cases of COVID-19 tops 209 million, U.S. daily average of deaths rises to 4-month highThe global tally for the coronavirus-borne illness climbed above 209.3 million as of early Thursday, while death toll rose to 4,393,138, according to . The U.S. led the world with a total of 37.16 million cases and 624,253 deaths. The daily average of new cases over the past seven days ticked back above 140,000 on Wednesday, after a brief one-day dip below it on Tuesday, according to . At 140,893, the daily average is up 47% from two weeks ago, and up from 32,305 from a month ago. The daily average for deaths rose to 809, up 97% from two weeks ago and the highest seen since early April, while the daily average of hospitalizations of 85,118 is up 56% from two weeks ago and the highest since early February. The number of people that have been fully vaccinated rose to 169.19 million, or 51.0% of the total U.S. population, according to . Federal health officials said Wednesday that those who have received the vaccines from Moderna Inc. and from Pfizer Inc. and BioNTech SE will be , starting in September.
1:55 a.m. Aug. 18, 2021 - By Tomi Kilgore
Coronavirus tally: Daily average of new cases slips, to snap a 39-day streak of increases based on NYT dataThe global tally for the coronavirus-borne illness climbed above 208.6 million as of early Wednesday, while death toll rose to 4,383,333, according to . The U.S. remained the world leader with 37.02 million cases and 623,322 deaths. On a daily basis, the seven-day average for cases slipped to 139,872 on Tuesday from 142,414 on Monday, to snap a 39-day streak of increases. The daily average was still up 52% from two weeks ago, and 4.5 times the average of 31,138 a month ago, . The daily average of deaths slipped to 696 on Tuesday from 704 on Monday, while hospitalizations increased to 83,291 from 82,519 on Monday, the most since Feb. 11. The number of people that have been fully vaccinated rose to 168.90 million, or 50.9% of the total U.S. population, according to . The U.S. is expected to announce Wednesday that most vaccinated Americans eight months after being fully vaccinated.
1:27 a.m. Aug. 17, 2021 - By Tomi Kilgore
Coronavirus tally: Global cases of COVID-19 nears 208 million, as U.S. reportedly set to recommend boostersThe global tally for the coronavirus-borne illness climbed above 207.9 million as of early Tuesday, while death toll rose to 4,372,554, according to . In the U.S., cases reached 36.89 million while deaths increased to 622,322, with both leading the world. On a daily basis, the seven-day average for cases grew to 141,365 on Monday, more than four times the daily average of 30,901 a month ago, and the most since Feb. 2, according to . The seven-day average for deaths rose to 704, up from 273 a month ago and the most since May 4, while hospitalizations rose to 81,556, up from 23,432 a month ago and the most since Feb. 12. The number of people that have been fully vaccinated rose to 168.69 million, or 50.8% of the total U.S. population, according to . The U.S. is set to announce that most vaccinated Americans shot eight months after being fully vaccinated, according to late Monday.
10:36 a.m. July 12, 2021 - By Jaimy Lee
J&J's COVID-19 shot may be connected to rare autoimmune disorder: reportShares of Johnson & Johnson were down 0.2% on Monday after the Washington Post that U.S. regulators plan to issue a new safety warning for the company's COVID-19 shot. The adenovirus viral vector, single-shot vaccine may be tied to rare instances of Guillain-Barré syndrome. The Post, citing data from the Centers for Disease Control and Prevention, reported that there have been 100 cases of the autoimmune disorder among the roughly 12.6 million people who have received the J&J shot. The vaccine, which received emergency authorization in February, has struggled to gain its footing among Americans after at a plant in Maryland and a confirmed association . J&J's stock is up 7.7% so far this year, while the broader S&P 500 has gained 16.3%.
3:14 a.m. June 22, 2021 - By Jaimy Lee
CDC committee to discuss rare cases of myocarditis occurring in people who have gotten their COVID-19 shotsFederal health experts plan to meet on Wednesday and Thursday rare but serious cases of myocarditis and pericarditis - inflammation of the heart - reported in about 800 people who have been vaccinated against COVID-19 with the Moderna Inc. or Pfizer Inc. mRNA vaccines, as of June 12. More than half of those cases occurred in people younger than 30, including about 75 teens, according to by Centers for Disease Control and Prevention officials. Though the cases of myocarditis are considered concerning, these cases are also very rare, occurring out of the roughly 300 million doses that have been administered in the U.S. The CDC's Advisory Committee on Immunization Practices is the same committee that recommends whether authorized or approved vaccines should be given to Americans. It met earlier this year to discuss safety concerns about Johnson & Johnson's COVID-19 shot.
6:40 a.m. June 4, 2021 - By Jaimy Lee
CDC director is 'concerned' about teens hospitalized for COVID-19, urges vaccinationThe Centers for Disease Control and Prevention is urging teens who are at least 12 years old to get vaccinated over concerns about the number of adolescents who are being hospitalized for COVID-19. The Pfizer Inc. and BioNTech SE vaccine was authorized in mid-May for teens between the ages of 12 and 15 years old. (It had already been authorized for those who are at least 16 years old since December.) "I am deeply concerned by the numbers of hospitalized adolescents and saddened to see the number of adolescents who required treatment in intensive care units or mechanical ventilation," CDC director Dr. Rochelle Walensky said in a statement. published Friday by the CDC said COVID-19 hospitalization rates among teens increased in March and April. About 200 teens were hospitalized for COVID-19 in 14 states between January and March of this year, 64 of whom were admitted to the intensive care unit during their stays.
3:15 a.m. June 1, 2021 - By Jaimy Lee
Abbott adjusts financial outlook, citing lower demand for COVID-19 testsShares of Abbott fell 2.3% in premarket trading on Tuesday after the diagnostics company updated its financial outlook for 2021, citing declining demand for its COVID-19 tests. Abbott said it now expects earnings per share of $2.75 to $2.95 and adjusted EPS of $4.30 to $4.50. The company in April said it projected EPS of at least $3.74 and adjusted EPS of at least $5.00 for the full year. There are a number of reasons why COVID-19 testing volume is declining in the U.S., including increasing vaccination rates and recent guidance from the Centers for Disease Control and Prevention that told vaccinated Americans if they are exposed to someone infected with the virus. Abbott has developed 12 COVID-19 tests, which generated $2.2 billion in the first quarter of the year. Abbott's stock is up 6.5% for the year, while the broader S&P 500 has gained 11.9%.
3:21 a.m. May 25, 2021 - MarketWatch
Moderna's COVID vaccine safe in adolescentsModerna Inc. said its Covid-19 vaccine was effective in children aged 12 to 17 in a new study, a finding that could clear the way for a second shot for use in adolescents. The Cambridge, Mass., company said the vaccine induced immune responses among children that were comparable to those seen in a study of adults last year.
4:01 a.m. May 17, 2021 - By Jaimy Lee
CDC: 3 million teens between ages of 12 and 17 have received at least one COVID-19 shotMore than 3 million teens between the ages of 12 and 17 years old have gotten at least one COVID-19 shot, as of Monday, . The public health agency does not break out more specific age categories on its COVID Data Tracker page; however, it says that about 157 million people over the age of 12 have received one dose of a vaccine, and about 154 million of those shots went to people who are at least 18 years old. the BioNTech SE and Pfizer Inc. two-dose, mRNA vaccine for use in teens between the ages of 12 and 15 years old, making it the first vaccine available in the U.S. to this group of younger teens. (The shot had previously been authorized for anyone who was at least 16 years old.)
2:13 a.m. May 13, 2021 - By Jaimy Lee
CDC committee recommends that Pfizer's COVID-19 shot be used in 12- to 15-year-oldsA Centers for Disease Control and Prevention committee voted 14-0-1 in favor of recommending that Pfizer Inc.'s COVID-19 vaccine can be safely used in 12- to 15-year-olds. The recommendation, made Wednesday by the CDC's Advisory Committee on Immunization Practices, follows a similar regulatory pathway as the original emergency-use authorization awarded in December. The expanded authorization for this age group by the Food and Drug Administration, the CDC committee voted Wednesday, and CDC director Dr. Rochelle Walensky signed off on the recommendation later that night. More than 60 million people in the U.S. have been immunized with the two-dose, mRNA vaccine developed by Pfizer and BioNTech SE , .
12:24 p.m. May 10, 2021 - By Claudia Assis
FDA authorizes emergency use of Pfizer, BioNTech COVID vaccine to kids 12-15The U.S. Food and Drug Administration late Monday authorized the emergency use of Pfizer Inc. and BioNTech SE COVID-19 vacccine for children between the ages of 12 and 15. Acting FDA commissioner Janet Woodcock called the expansion of the emergency use a "significant step in the fight against the COVID-19 pandemic." The FDA had granted the vaccine emergency use for people 16 and older. "Parents and guardians can rest assured that the agency undertook a rigorous and thorough review of all available data, as we have with all of our COVID-19 vaccine emergency use authorizations," she said. From March 2020 through April 2021, about 1.5 million COVID-19 cases in kids 11 to 17 years of age have been reported to the Centers for Disease Control and Prevention, the FDA said.
9:36 a.m. April 30, 2021 - By Robert Schroeder
U.S. to restrict travel from India as COVID cases surgeThe Biden administration will restrict travel from India beginning May 4, the White House said Friday. "The policy will be implemented in light of extraordinarily high COVID-19 caseloads and multiple variants circulating in India," a statement said. The administration is acting on the advice of the Centers for Disease Control and Prevention. India on Friday , as the country's army opened its hospitals in the latest effort to address a dire humanitarian crisis.
7:41 a.m. April 27, 2021 - By Jaimy Lee
CDC: Small groups of people can gather outside without masksThe Centers for Disease Control and Prevention said Tuesday that people who are fully vaccinated no longer need to wear a mask at small outdoor gatherings with both vaccinated and unvaccinated people or when dining outdoors with people from multiple households. "Generally, for vaccinated people, outdoor activities without a mask are safe," CDC director Dr. Rochelle Walensky said during a media briefing on Tuesday. However, the public-health agency also said that even if someone is fully vaccinated, they should still wear a mask at crowded outdoor events or for any indoor activities, like going to hair salons, malls, museums, worship services, or indoor restaurants. The CDC considers people to be fully vaccinated two weeks after getting the Johnson & Johnson shot or two weeks after getting the second dose of the Moderna Inc. or Pfizer Inc. vaccines.
5:07 a.m. April 23, 2021 - By Jaimy Lee
CDC committee to meet today to discuss J&J's COVID-19 shotA Centers for Disease Control and Prevention's advisory committee is scheduled to meet for a second time on Friday, April 23, to discuss rare safety concerns about Johnson & Johnson's COVID-19 vaccine. Of the 6.8 million people in the U.S. who have received the J&J's shot, six women have been hospitalized with severe blood clots after receiving the vaccine. As a result, federal health officials recommended a "pause" in using the vaccine, a decision when the CDC's Advisory Committee on Immunization Practices met earlier this week. The is scheduled for 11 a.m. to 5 p.m. Eastern Time on April 23. It will be webcast to the public.
8:33 p.m. April 18, 2021 - By Quentin Fottrell
What determines when Americans reclaim their ‘liberty’? Here is Dr. Fauci’s answer Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases, appeared Thursday before a House subcommittee on the coronavirus pandemicAnthony Fauci, the director of the National Institute of Allergy and Infectious Diseases, was appearing before a House Select Subcommittee on the Coronavirus Crisis.
9:10 a.m. April 13, 2021 - By Jaimy Lee
CDC committee to hold emergency meeting for J&J's COVID-19 shot on Wednesday afternoonThe Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices is scheduled to hold an on Wednesday, starting at 1:30 p.m. Eastern Time, in response to a federal recommendation made Tuesday to temporarily halt immunizations using Johnson & Johnson's COVID-19 vaccine. The recommendation was made after six people who received the J&J shot were diagnosed with severe blood clots in combination with low levels of blood platelets. About 6.8 million people in the U.S. in total have been administered the J&J vaccine. The meeting, which will be publicly webcast, is expected to conclude with a vote about whether the vaccine should continue to be used, how it should be used going forward, or how people who develop blood clots as a result of the vaccine should be treated. The ACIP after the Food and Drug Administration granted the emergency authorization.
9:10 a.m. April 13, 2021 - By Jaimy Lee
CDC committee to hold emergency meeting for J&J's COVID-19 shot on Wednesday afternoonThe Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices is scheduled to hold an on Wednesday, starting at 1:30 p.m. Eastern Time, in response to a federal recommendation made Tuesday to temporarily halt immunizations using Johnson & Johnson's COVID-19 vaccine. The recommendation was made after six people who received the J&J shot were diagnosed with severe blood clots in combination with low levels of blood platelets. About 6.8 million people in the U.S. in total have been administered the J&J vaccine. The meeting, which will be publicly webcast, is expected to conclude with a vote about whether the vaccine should continue to be used, how it should be used going forward, or how people who develop blood clots as a result of the vaccine should be treated. The ACIP after the Food and Drug Administration granted the emergency authorization.
5:06 a.m. April 13, 2021 - By Tomi Kilgore
Moderna, BioNTech stocks surge after regulators halt use of J&J vaccine Shares of Moderna Inc. shot up 8.6% in morning trading, BioNTech SE ran up 5.7% toward a 4-month high and Pfizer Inc. climbed 1.1% toward a 3-month high, after U.S. health regulators paused the use of Johnson & Johnson's COVID-19 vaccine . Meanwhile, J&J shares shed $2.98, or 1.8%, to shave about 20 points of the Dow Jones Industrial Average's price, as the Dow dropped 132 points, or 0.4%. Moderna's two-dose COVID-19 vaccine, and the two-dose vaccine from Pfizer and partner BioNTech are mRNA vaccines while J&J's one-dose vaccine is an adenovirus vaccine. The Centers for Disease Control and Prevention and the Food and Drug Administration said there have been six cases of blood clotting out of the roughly six million people who have received the J&J vaccine, all of who were women between the ages of 18 and 48.
6:59 a.m. April 9, 2021 - By Jaimy Lee
J&J's shipment of COVID-19 shots to drop next weekJohnson & Johnson is expected to ship 700,000 doses of its COVID-19 vaccine on the week of April 12; however, that number is significantly lower than the roughly 4.9 million doses of J&J's vaccine that were allocated to states on the week of April 5. This is according to . In total, J&J has shipped about 11.2 million doses of its single-shot vaccine since it was authorized in February, including the 700,000 doses expected to go out the week of April 12. J&J that a batch of its vaccines did not meet quality standards at a plant run by Emergent BioSolutions Inc. , its U.S. manufacturing partner. White House officials said Friday that they expect J&J to begin delivering 8 million doses per week by the end of April. J&J's stock is up 3.5% so far this year, while the broader S&P 500 has gained 8.5%.
5:06 a.m. April 7, 2021 - By Jaimy Lee
U.S. government to study allergic reactions to COVID-19 vaccinesThe National Institutes of Health said Wednesday that it started a assessing allergic reactions to the mRNA COVID-19 vaccines developed by Moderna Inc. and BioNTech SE /Pfizer Inc. . The aim is to understand who is at increased risk, including people with a history of allergic reactions or those who have been diagnosed with a mast cell disorder. (Mast cells are part of the body's immune system. When those cells mutate, it can cause one of several rare disorders.) The Phase 2 clinical trial, which is being funded by the National Institute of Allergy and Infectious Diseases, will enroll 3,400 adults who fit one of three categories: people who have previously reported a severe allergic reaction to food, insects, or a medication; people who have been diagnosed with a mast cell disorder; or individuals without a history of either. The Centers for Disease Control and Prevention that anaphylaxis as a result of a COVID-19 vaccine occurs in up to 5 people out of every 1 million who have been vaccinated. These events "almost always" occur within 30 minutes of receiving the shot.
2:02 a.m. April 1, 2021 - By Ciara Linnane
Pfizer, BioNTech say study of COVID-19 patients six months after second vaccine dose proved it is safe and effectivePfizer Inc. and German partner BioNTech SE said Thursday a study of COVID-19 patients six months after receiving a second dose of their vaccine BNT162b2 confirmed its high efficacy and lack of serious safety concerns. The companies said an analysis of 927 confirmed symptomatic cases of COVID-19 showed the vaccine had a 91.3% efficacy against the illness, measured seven days through up to six months after the second dose. The vaccine was 100% effective in preventing severe disease as defined by the U.S. Centers for Disease Control and Prevention and 95.3% effective in preventing severe disease as defined by the U.S. Food and Drug Administration. The vaccine also proved to be 100% effective in preventing COVID-19 cases when used against the South African variant, which is more infectious than the original virus. Experts have worried that new variants might prove more resistant to the vaccines that have won emergency use authorization from regulators. Pfizer and BioNTech said they have now evaluated vaccine safety in more than 44,000 participants 16 years of age and older, with more than 12,000 vaccinated participants having at least six months follow-up after a second dose. "These data confirm the favorable efficacy and safety profile of our vaccine and position us to submit a Biologics License Application to the U.S. FDA," said Pfizer Chief Executive Albert Bourla. Prizer shares were up 0.2% premarket, while BioNTech shares were up 1.2%.
1:28 a.m. March 16, 2021 - By Tomi Kilgore
Coronavirus tally: U.S. daily case and death tally edges up, but average for the week falls 18%The global tally for confirmed cases of the coronavirus that causes COVID-19 climbed to 120,273,942 on Tuesday, according to , with the U.S. accounting for nearly one-quarter of the cases with 29,495,422. The global death toll grew to 2,662,067, while the U.S. death count rose to 535,628, or one-fifth of the worldwide total. On Monday, new cases increased to at least 57,081 from 38,034 on Sunday, and deaths rose to at least 751 people from 572 the day before, . The daily average of new cases over the past week was 55,153, down 18% from the average two weeks earlier. On the vaccine front, the show that 135,847,835 vaccine doses have been delivered, while 109,081,860 arms have been jabbed, including 71,054,445 people who have received at least one dose and 38,335,432 people who have been fully vaccinated. Outside of the U.S., Brazil has the second highest death toll at 279,286 and is second by cases at 11,519,609. India is third worldwide in cases with 11,409,831 million and fourth in deaths at 158,856. Mexico has the third highest death toll at 194,944 and 13th highest case tally at 2,167,729. The U.K. has the fifth-most cases at 4,276,840, while the death toll of 125,817 is fifth highest in the world and the highest in Europe.
6:16 a.m. March 5, 2021 - By Jaimy Lee
U.S. to open new COVID-19 vaccination sites in Atlanta and ClevelandThe Biden administration said Friday that it is opening two new COVID-19 vaccination centers, this time in Atlanta and Cleveland. Both sites will be managed by the Federal Emergency Management Agency and will each have the capacity to administer 6,000 shots per day, according to comments made by Andy Slavitt, the White House's senior advisor for the COVID-19 response during a White House press briefing on Friday. The addition of the two new sites means that there will be eight FEMA-supported vaccination sites in the U.S. About 82 million shots have been administered in the U.S., and nearly 28 million people have received both doses of the first two authorized COVID-19 vaccines in the U.S., according to the latest data from the Centers for Disease Control and Prevention.
4:34 a.m. Feb. 16, 2021 - By Tomi Kilgore
Moderna moves up expected delivery of 300 million COVID-19 vaccine doses to end of JulyModerna Inc. provided on Tuesday an update of the supply of its COVID-19 vaccine, saying it expects to deliver 100 million doses to the U.S. Government by the end of March. The company said it moved up the expected delivery of its second 100 million doses to the end of May from the end of June, and its third 100 million doses to the end of July, from the end of September. To date, the company said it has delivered 45.4 million doses of its vaccine, and the Centers for Disease Control and Prevention said about 25.5 million doses of the vaccine have been administered. Moderna's vaccine requires two doses, spaced weeks apart. Moderna said it does not plan to stockpile significant quantities of doses to smooth shipments, as it has chosen to ship doses to the government as they are produced. Moderna's stock, which edged up 0.1% in premarket trading, has soared 87.6% over the past three months through Friday, while the S&P 500 has gained 8.5%.
7:56 a.m. Jan. 28, 2021 - By Jaimy Lee
South Carolina officials confirm first two cases of South African variant in the U.S. Health officials in South Carolina confirmed that two people in the state have tested positive for a new coronavirus variant that was first identified in South Africa. These are the first two confirmed cases of the more infectious variant in the U.S. The South African strain, which is called B.1.351, is one of several new variants wthat have emerged around the world and are raising concern among government officials and medical experts over their transmissibility. The South Carolina Department of Health and Environmental Control confirmed the two cases in residents of the Lowcountry and the Pee Dee region in a on Thursday. Neither adult has a travel history, and they do not know each other, officials said. Health departments use genomic sequencing to identify new strains or variants among COVID-19 test samples; this is how the South Carolina health department identified both cases. Another variant, the B.1.1.7, which was first detected in the United Kingdom, has infected more than 300 people in the U.S. so far, according to the from the Centers for Disease Control and Prevention. This variant is also thought to be more infectious. This week, Moderna Inc. said a laboratory study demonstrated that its COVID-19 vaccine against the B.1.351 strain, and Regeneron Pharmaceuticals Inc. said one of the two antibodies used in its COVID-19 treatment .
3:24 a.m. Jan. 25, 2021 - By Jaimy Lee
CDC says doses of COVID-19 vaccines can be spaced out by up to 42 daysThe Centers for Disease Control and Prevention updated for vaccine administration to say that it's okay to space out the first and second doses of the currently available COVID-19 vaccines by up to 42 days, if necessary. The regulatory labels say that doses of the BioNTech SE and Pfizer Inc. vaccine should be spaced 21 days apart, while the second dose of Moderna Inc.'s 's vaccine is expected to be administered 28 days after the first dose. "However, if it is not feasible to adhere to the recommended interval, the second dose of Pfizer-BioNTech and Moderna COVID-19 vaccines may be scheduled for administration up to 6 weeks (42 days) after the first dose," the CDC said. The United Kingdom has also said of its authorized vaccines, which include the AstraZeneca and University of Oxford vaccine in addition to the ones developed by BioNTech/Pfizer and Moderna, as needed. Over the past 12 months, BioNTech's stock has rallied 209.9%, Pfizer shares are down 3.1%, and Moderna's stock has soared 520.3%. The S&P 500 has gained 15.6% over the past year.
3:20 a.m. Jan. 25, 2021 - By Jaimy Lee
CDC: Moderna's COVID-19 vaccine can cause allergic reaction in some peopleThe Centers for Disease Control and Prevention said Friday that Moderna Inc.'s COVID-19 vaccine produces an allergic reaction in a small percentage of people, similar to the agency's findings about the coronavirus vaccine developed by BioNTech SE and Pfizer Inc. . Moderna's stock was up 1.6% in premarket trading on Monday. There were 10 cases of anaphylaxis among the roughly 4 million doses administered between Dec. 21 and Jan. 10, according to the . Both vaccines are mRNA-based vaccines, with similar efficacy rates in clinical trials. They are the only two COVID-19 vaccines that have been authorized in the U.S. so far during the pandemic. The CDC that health care providers prepare for the possibility of anaphylaxis among some people who get vaccinated. Moderna's stock has soared 520.3% over the past 12 months, while the S&P 500 is up 15.6%.
9:50 a.m. Jan. 19, 2021 - By Ciara Linnane
U.S. climbs above 400,000 COVID-19 fatalities as California becomes first state with 3 million confirmed cases L.A. County air quality regulator lifts limit on how many cremations can be performed to help clear backlog of bodiesThe number of global cases of the coronavirus-borne illness COVID-19 rose above 95.9 million on Tuesday, and the U.S. edged closer to 400,000 deaths, with California becoming the first state with more than three million confirmed cases.
Browse topics:

Filter results by

Location

Us (207)

Asia Pacific (30)

Europe (30)

Eu (22)

Latin America (13)

China (11)

Link to MarketWatch's Slice.